Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
2.30000.0000 (0.00%)
At close: 03:38PM EDT
Full screen
Previous close2.3000
Open2.3000
Bid2.3000 x N/A
Ask2.3300 x N/A
Day's range2.3000 - 2.3700
52-week range0.8000 - 3.0000
Volume12,925
Avg. volume23,826
Market cap49.204M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.2720
Earnings date12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.75
  • CNW Group

    Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the grant of a patent and a notice of allowance for EP-104IAR.

  • CNW Group

    Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced today that its CEO, Dr. James Helliwell, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.

  • CNW Group

    Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.